Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

ABSTRACT:

SUBMITTER: Eskelund CW 

PROVIDER: S-EPMC6278958 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature